Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial
Merck Sharp & Dohme LLC
Jason J Luke; Piotr Rutkowski; Paola Queirolo; Michele Del Vecchio; Jacek Mackiewicz; Vanna Chiarion-Sileni; Luis de la Cruz Merino; Muhammad A Khattak; Dirk Schadendorf; Georgina V Long; Paolo A Ascierto; Mario Mandala; Federica De Galitiis; Andrew Haydon; Reinhard Dummer; Jean-Jacques Grob; Caroline Robert; Matteo S Carlino; Peter Mohr; Andrew Poklepovic; Vernon K Sondak; Richard A Scolyer; John M Kirkwood; Ke Chen; Scott J Diede; Sama Ahsan; Nageatte Ibrahim; Alexander M M Eggermont; KEYNOTE-716 Investigators